Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Oncogenomics
  • Published:

Frequent epigenetic inactivation of RASSF1A and BLU genes located within the critical 3p21.3 region in gliomas

Oncogene volume 23, pages 2408–2419 (2004)Cite this article

Abstract

RASSF1A is a major tumor suppressor gene located at 3p21.3. We investigated the role of aberrant promoter region hypermethylation of RASSF1A in a large series of adult gliomas. RASSF1A was frequently methylated in both primary tumors (36/63; 57%) and tumor cell lines (7/7; 100%). Hypermethylation of RASSF1A in glioma cell lines correlated with loss of expression and treatment with a demethylating agent-reactivated RASSF1A gene expression. Furthermore, re-expression of RASSF1A suppressed the growth of glioma cell line H4 in vitro. Next, we investigated whether other members of the RASSF gene family were also inactivated by methylation. NORE1B and RASSF3 were not methylated in gliomas, while NORE1A and RASSF5/AD037 demonstrated methylation in glioma cell lines but not in primary tumors. We then investigated the methylation status of three other candidate 3p21.3 tumor suppressor genes. CACNA2D2 and SEMA3B were not frequently methylated, but the BLU gene located just centromeric to RASSF1 was frequently methylated in glioma cell lines (7/7) and in 80% (35/44) of glioma tumors. In these tumor cell lines, BLU expression was restored after treatment with a demethylating agent. Loss of BLU gene expression in glioma tumors correlated with BLU methylation. There was no association between RASSF1A and BLU methylation. RASSF1A methylation increased with tumor grade, while BLU methylation was seen at similar frequencies in all grades. Our data implicate RASSF1A and BLU promoter methylation in the pathogenesis of adult gliomas, while other RASSF family members and CACNA2D2 and SEMA3B appear to have only minor roles. In addition, RASSF1A and BLU methylation appear to be independent and specific events and not due to region-wide changes in DNA methylation.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  • Agathanggelou A, Bieche I, Ahmed-Choudhury J, Nicke B, Dammann R, Baksh S, Gao B, Minna JD, Downward J, Maher ER and Latif F . (2003a). Cancer Res., 63, 5344–5351.

  • Agathanggelou A, Dallol A, Zochbauer-Muller S, Morrissey C, Honorio S, Hesson L, Martinsson T, Kuo M, Yuen PW, Maher ER, Minna JD and Latif F . (2003b). Oncogene, 22, 1580–1588.

  • Agathanggelou A, Honorio S, Macartney DP, Martinez A, Dallol A, Rader J, Fullwood P, Chauhan A, Walker R, Shaw JA, Hosoe S, Lerman MI, Minna JD, Maher ER and Latif F . (2001). Oncogene, 20, 1509–1518.

  • Astuti D, Agathanggelou A, Honorio S, Dallol A, Martinsson T, Kogner P, Cummins C, Neumann HP, Voutilainen R, Dahia P, Eng C, Maher ER and Latif F . (2001). Oncogene, 20, 7573–7577.

  • Bieche I, Parfait B, Le Doussal V, Olivi M, Rio MC, Lidereau R and Vidaud M . (2001). Cancer Res., 61, 1652–1658.

  • Burbee DG, Forgacs E, Zochbauer-Muller S, Shivakumar L, Fong K, Gao B, Randle D, Kondo M, Virmani A, Bader S, Sekido Y, Latif F, Milchgrub S, Toyooka S, Gazdar AF, Lerman MI, Zabarovsky E, White M and Minna JD . (2001). J. Natl. Cancer Inst., 93, 691–699.

  • Carboni GL, Gao B, Nishizaki M, Xu K, Minna JD, Roth JA and Ji L . (2003). Oncogene, 22, 615–626.

  • Dallol A, Da Silva NF, Viacava P, Minna JD, Bieche I, Maher ER and Latif F . (2002). Cancer Res., 62, 5874–5880.

  • Dallol A, Krex D, Hesson L, Eng C, Maher ER and Latif F . (2003b). Oncogene, 22, 4611–4616.

  • Dallol A, Morton D, Maher ER and Latif F . (2003a). Cancer Res., 63, 1054–1058.

  • Dammann R, Li C, Yoon JH, Chin PL, Bates S and Pfeifer GP . (2000). Nat. Genet., 25, 315–319.

  • Esteller M, Corn PG, Urena JM, Gabrielson E, Baylin SB and Herman JG . (1998). Cancer Res., 58, 4515–4518.

  • Esteller M, Hamilton SR, Burger PC, Baylin SB and Herman JG . (1999). Cancer Res., 59, 793–797.

  • Feinstein PG, Kornfeld K, Hogness DS and Mann RS . (1995). Genetics, 140, 573–586.

  • Harada K, Toyooka S, Shivapurkar N, Maitra A, Reddy JL, Matta H, Miyajima K, Timmons CF, Tomlinson GE, Mastrangelo D, Hay RJ, Chaudhary PM and Gazdar AF . (2002). Cancer Res., 62, 5897–5901.

  • Herman JG, Graff JR, Myohanen S, Nelkin BD and Baylin SB . (1996). Proc. Natl. Acad. Sci. USA, 93, 9821–9826.

  • Hesson L, Dallol A, Minna JD, Maher ER and Latif F . (2003). Oncogene, 22, 947–954.

  • Holland EC . (2001). Nat. Rev. Genet., 2, 120–129.

  • Honorio S, Agathanggelou A, Schuermann M, Pankow W, Viacava P, Maher ER and Latif F . (2003a). Oncogene, 22, 147–150.

  • Honorio S, Agathanggelou A, Wernert N, Rothe M, Maher ER and Latif F . (2003b). Oncogene, 22, 461–466.

  • Katzenellenbogen RA, Baylin SB and Herman JG . (1999). Blood, 93, 4347–4353.

  • Khokhlatchev A, Rabizadeh S, Xavier R, Nedwidek M, Chen T, Zhang XF, Seed B and Avruch J . (2002). Curr. Biol., 12, 253–265.

  • Kominsky SL, Argani P, Korz D, Evron E, Raman V, Garrett E, Rein A, Sauter G, Kallioniemi OP and Sukumar S . (2003). Oncogene, 22, 2021–2033.

  • Kuroki T, Trapasso F, Yendamuri S, Matsuyama A, Alder H, Williams NN, Kaiser LR and Croce CM . (2003). Cancer Res., 63, 3352–3355.

  • LeBoeuf RD, Ban EM, Green MM, Stone AS, Propst SM, Blalock JE and Tauber JD . (1998). J. Biol. Chem., 273, 361–368.

  • Lerman MI and Minna JD . (2000). Cancer Res., 60, 6116–6133.

  • Liu XQ, Chen HK, Zhang XS, Pan ZG, Li A, Feng QS, Long QX, Wang XZ and Zeng YX . (2003). Int. J. Cancer, 106, 60–65.

  • Louis DN, Pomeroy SL and Cairncross JG . (2002). Cancer Cell, 1, 125–128.

  • Lusher ME, Lindsey JC, Latif F, Pearson ADJ, Ellison DW and Clifford SC . (2002). Cancer Res., 62, 5906–5911.

  • Masselink H and Bernards R . (2000). Oncogene, 19, 1538–1546.

  • Michelson RJ, Collard MW, Ziemba AJ, Persinger J, Bartholomew B and Huggenvik JI . (1999). J. Biol. Chem., 274, 30510–30519.

  • Mitic LL, Van Itallie CM and Anderson JM . (2000). Am. J. Physiol. Gastrointest. Liver Physiol., 279, G250–G254.

  • Ortiz-Vega S, Khokhlatchev A, Nedwidek M, Zhang XF, Dammann R, Pfeifer GP and Avruch J . (2002). Oncogene, 21, 1381–1390.

  • Pfeifer GP, Yoon JH, Liu L, Tommasi S, Wilczynski SP and Dammann R . (2002). Biol. Chem., 383, 907–914.

  • Shivakumar L, Minna J, Sakamaki T, Pestell R and White MA . (2002). Mol. Cell. Biol., 22, 4309–4318.

  • Shivapurkar N, Toyooka S, Eby MT, Huang CX, Sathyanarayana UG, Cunningham HT, Reddy JL, Brambilla E, Takahashi T, Minna JD, Chaudhary PM and Gazdar AF . (2002). Cancer Biol. Ther., 1, 65–69.

  • Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA, Behm FG, Look AT, Lahti JM and Kidd VJ . (2000). Nat. Med., 6, 529–535.

  • Tomizawa Y, Sekido Y, Kondo M, Gao B, Yokota J, Roche J, Drabkin H, Lerman MI, Gazdar AF and Minna JD . (2001). Proc. Natl. Acad. Sci. USA, 98, 13954–13959.

  • Tommasi S, Dammann R, Jin SG, Zhang XF, Avruch J and Pfeifer GP . (2002). Oncogene, 21, 2713–2720.

  • Wolford JK and Prochazka M . (1998). Gene, 212, 103–109.

Download references

Acknowledgements

This work was in part supported by Cancer Research UK.

Author information

Authors and Affiliations

  1. Division of Reproductive and Child Health, Section of Medical and Molecular Genetics, University of Birmingham, Birmingham, B15 2TT, UK

    Luke Hesson, Eamonn R Maher & Farida Latif

  2. Laboratoire d'Oncogénétique – INSERM E0017, Centre René Huguenin, 35, rue Dailly, St-Cloud, F-92210, France

    Ivan Bièche

  3. Department of Neurosurgery, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Fetscherstraße 74, Dresden, 01307, Germany

    Dietmar Krex

  4. Fédération neurologique Mazarin and Unité INSERM U495, Hôpital de la Salpêtrière, Paris, France

    Emmanuelle Criniere & Khê Hoang-Xuan

  5. Cancer Research UK Renal Molecular Oncology Research Group, University of Birmingham, Birmingham, B15 2TG, UK

    Eamonn R Maher & Farida Latif

Authors
  1. Luke Hesson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ivan Bièche
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dietmar Krex
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Emmanuelle Criniere
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Khê Hoang-Xuan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Eamonn R Maher
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Farida Latif
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Farida Latif.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hesson, L., Bièche, I., Krex, D. et al. Frequent epigenetic inactivation of RASSF1A and BLU genes located within the critical 3p21.3 region in gliomas. Oncogene 23, 2408–2419 (2004). https://doi.org/10.1038/sj.onc.1207407

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1207407

Keywords

This article is cited by

Search

Advanced search

Quick links